Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
2.280
-0.020 (-0.87%)
May 30, 2025, 3:12 PM - Market open
Larimar Therapeutics Employees
Larimar Therapeutics had 65 employees as of December 31, 2024. The number of employees increased by 23 or 54.76% compared to the previous year.
Employees
65
Change (1Y)
23
Growth (1Y)
54.76%
Revenue / Employee
n/a
Profits / Employee
-$1,465,092
Market Cap
145.98M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
LRMR News
- 4 weeks ago - Larimar Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 3 months ago - Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 4 months ago - Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - GlobeNewsWire
- 5 months ago - Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better - Seeking Alpha
- 5 months ago - What's Going On With Larimar Therapeutics Stock On Tuesday? - Benzinga
- 5 months ago - Why Is Larimar Therapeutics Stock Trading Lower On Monday? - Benzinga
- 5 months ago - Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia - GlobeNewsWire